NYSE - Delayed Quote • USD
Novo Nordisk A/S (NVO)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:59 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 8 | 8 |
Avg. Estimate | 0.74 | 0.76 | 3.37 | 4.05 |
Low Estimate | 0.68 | 0.71 | 3.16 | 3.55 |
High Estimate | 0.78 | 0.83 | 3.59 | 4.78 |
Year Ago EPS | 0.64 | 0.63 | 2.66 | 3.37 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 7 | 7 |
Avg. Estimate | 9.06B | 9.58B | 41.52B | 49.49B |
Low Estimate | 8.78B | 9.28B | 39.61B | 44.12B |
High Estimate | 9.44B | 9.78B | 43.73B | 53.34B |
Year Ago Sales | 7.59B | 7.97B | 33.13B | 41.52B |
Sales Growth (year/est) | 19.50% | 20.30% | 25.30% | 19.20% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.63 | 0.65 | 0.73 | 0.64 |
EPS Actual | 0.64 | 0.63 | 0.73 | 0.7 |
Difference | 0.01 | -0.02 | 0 | 0.06 |
Surprise % | 1.60% | -3.10% | 0.00% | 9.40% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.74 | 0.76 | 3.37 | 4.05 |
7 Days Ago | 0.73 | 0.75 | 3.33 | 4 |
30 Days Ago | 0.75 | 0.77 | 3.36 | 3.96 |
60 Days Ago | 0.78 | 0.8 | 3.32 | 3.94 |
90 Days Ago | 0.81 | 0.78 | 3.19 | 3.76 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 2 | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | NVO | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 15.60% | -- | -- | 6.50% |
Next Qtr. | 20.60% | -- | -- | 12.00% |
Current Year | 26.70% | -- | -- | 5.30% |
Next Year | 20.20% | -- | -- | 13.10% |
Next 5 Years (per annum) | 2.80% | -- | -- | 11.09% |
Past 5 Years (per annum) | 19.23% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
Initiated | BMO Capital: Outperform | 4/12/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/20/2024 |
Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/8/2024 |
Related Tickers
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.06%
MRNA Moderna, Inc.
107.97
+1.69%
CRSP CRISPR Therapeutics AG
53.91
+0.34%
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
IBRX ImmunityBio, Inc.
7.35
+43.84%
REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
ALT Altimmune, Inc.
7.26
+0.83%
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
NVAX Novavax, Inc.
4.0900
+3.54%